ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3008

Role of PTP4A1 Tyrosine Phosphatase in Systemic Sclerosis

Cristiano Sacchetti1, Stephanie Stanford2, Yunpeng Bai3, Zhong-Yin Zhang4, Amin Gholami5, Gregory Seumois6, Maria Piera-Velazquez7, Sergio A. Jimenez8 and Nunzio Bottini1, 1Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 2Cell Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 3Indiana University, School of Medicine, Indianapolis, IN, 4Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, 5Bioinformatics Core, La Jolla Institute for Allergy and immunology, La Jolla, CA, 6Sequencing Facility, La Jolla Institute for Allergy and immunology, La Jolla, CA, 7Dermatology and Cutaneous Biology, Jefferson Medical College, Philadelphia, PA, 8Div Connective Tissue Diseases, Thomas Jefferson Univ, Philadelphia, PA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Fibroblasts, fibrosis, Mouse model, signal transduction and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc) is a multi-system autoimmune connective tissue disorder that leads to fibrosis of the skin and internal organs, resulting in significant patient morbidity and mortality. The fibroblast is considered a key target cell type for possible therapies aimed at modifying excessive deposition of extracellular matrix in affected organs. Several studies have assessed the role of protein tyrosine kinases (PTKs) in the pathophysiology of SSc fibroblasts and fibrosis. However the role of protein tyrosine phosphatases (PTPs), a family of enzymes that naturally balance the action of PTKs in signal transduction, in fibrosis remains mostly unexplored.

Methods: We analyzed the mRNA expression profile of all the PTPs (109 genes) in primary dermal fibroblasts from 9 patients with diffuse SSc compared to 9 healthy subjects. Whole transcriptome analysis by Next Generation Sequencing (NGS) was performed on normal human dermal fibroblasts (NHDF) subjected to silencing of the PTP4A1 gene. In NHDF we investigated the effects of PTP4A1 silencing on TGFbeta1 stimulated COL1A2 and ACTA2 gene expression and on SMAD3 and alphaSMA protein level by qPCR and immunoblotting, respectively. Luciferase assays were performed using a SMAD reporter in HEK 293T cell and in vivo experiments were carried out in mice using a bleomycin-induced fibrosis model.

Results:  PTP4A1 gene displayed increased expression in SSc dermal fibroblast lines studied (Mann-Whitney test, p<0.05). NGS of normal dermal fibroblasts showed that silencing of PTP4A1 correlated with reduced expression of human pro-fibrotic genes and in particular of SMAD3, which pointed to a possible role of PTP4A1 in the TGFbeta-dependent pro-fibrotic pathway. NGS data for SMAD3 and other pro-fibrotic genes were confirmed at the protein level by immunoblotting. Co-transfection of HEK 293T with a human PTP4A1-encoding pCDNA4 vector together with a luciferase SMAD reporter showed that PTP4A1 enhances activation of SMAD signaling after TGFbeta1 stimulation (Mann-Whitney test, p<0.05). In vivo experiments showed that knockout of PTP4A1 significantly attenuates bleomycin-induced fibrosis model in mice.

Conclusion: These results suggest that PTP4A1, a PTP overexpressed in SSc dermal fibroblasts, plays a role in the pathogenesis of SSc by promoting pro-fibrotic TGFbeta/SMAD3 signaling.


Disclosure: C. Sacchetti, None; S. Stanford, None; Y. Bai, None; Z. Y. Zhang, None; A. Gholami, None; G. Seumois, None; M. Piera-Velazquez, None; S. A. Jimenez, None; N. Bottini, None.

To cite this abstract in AMA style:

Sacchetti C, Stanford S, Bai Y, Zhang ZY, Gholami A, Seumois G, Piera-Velazquez M, Jimenez SA, Bottini N. Role of PTP4A1 Tyrosine Phosphatase in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/role-of-ptp4a1-tyrosine-phosphatase-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/role-of-ptp4a1-tyrosine-phosphatase-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology